Latest News and Press Releases

Initiated Phase III part of the Phase II/III adaptive, randomized, controlled trial in patients with severe COVID-19 induced pneumoniaPublished encouraging data from Phase II part of COVID-19 trial in...

Thomas Taapken, Ph.D. appointed Chief Financial OfficerJordan Zwick promoted to Chief Strategy Officer JENA, Germany, Sept. 17, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage...

First site initiated for enrollment in the NetherlandsRegulatory approval granted to start trial in GermanyAdditional sites to be added in the US, EU and other regionsEncouraging Phase II data...

JENA, Germany, Aug. 06, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...

Announced encouraging results from the Phase II portion of the Phase II/III adaptive, randomized, controlled trial in patients with COVID-19 induced pneumonia, showing a trend in lower 28-day...

50% lower all-cause mortality rate and other efficacy trends were shown with IFX-1 in initial data from the randomized exploratory Phase II part of the Phase II/III trialSubject to regulatory...

IFX-1 treatment showed a trend in lower 28-day all-cause mortality rate, along with trends of maintained kidney function, faster normalization in lymphocyte counts and greater reduction in LDH in...

End of Phase II meeting with the FDA scheduled to discuss the path forward for IFX-1 in Hidradenitis SuppurativaInitial promising results reported in Pyoderma GangraenosumPart 1 of adaptive randomized...

End of Phase 2 FDA meeting scheduled to discuss the path forward for IFX-1 in Hidradenitis SuppurativaInitial promising results reported in Pyoderma GangraenosumPart 1 of adaptive randomized trial in...

InflaRx has dosed the first patient in an adaptive randomized controlled clinical study with IFX-1 in patients with severe COVID-19 pneumonia in the NetherlandsInflaRx received initial positive human...